European Archives - Page 294 of 1217 - European Medical Journal

Spoonful of Technology: Sept-Oct

Take a look at the latest examples of how pharma and its partners are working together to develop technology to solve key challenges.

ABPI welcomes the UK Chancellor’s new Budget

The Association of the British Pharmaceutical Industry has expressed support for the first Labour budget in 14 years.

Potential Survival Benefits of Transplant for TP53-Mutated Acute Myeloid Leukemia

A recent multicenter study led by researchers including Talha Badar and Moazzam Shahzad has highlighted the challenging prognosis of TP53-mutated acute myeloid leukemia.

MRI Screening Reduces Unnecessary Biopsies in Prostate Cancer

Prostate cancer remains a significant health concern for men, particularly those aged between 50 and 60 years.

Asthma Drug Does Not Reduce COVID-19 Symptom Duration

A NEW clinical trial has found that the asthma drug montelukast does not shorten the duration of symptoms for mild-to-moderate COVID-19 patients compared to a placebo.

MRI Technique Predicts Breast Cancer Subtypes and Treatment Response

A technique, known as time-dependent diffusion MRI-based microstructural mapping, has been shown to improve the prediction of breast cancer molecular subtypes and treatment response.

Penicillin Reduces the Risk of Parkinson’s Disease

Individuals who received multiple courses of penicillin antibiotics had a 15% lower risk of developing Parkinson’s disease (PD), while those who used antifungal medications had a 16% higher risk.

Dual Bronchodilator Therapy Shows Promise for COPD Smokers

A new study has shown that dual bronchodilator therapy can help reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD), with notable differences in efficacy between current and former smokers.

Teleprehabilitation Effective for Reducing Adverse Events After Cardiac Surgery

A RECENT study found that multimodal, personalised teleprehabilitation significantly reduced major adverse cardiovascular events (MACE) in patients undergoing elective cardiac surgery.

SGLT2 Inhibitors More Effective in Reducing Kidney Complications

A real-world study has found that SGLT2 inhibitors and GLP-1 receptor agonists are more effective at reducing kidney complications in adults with Type 2 diabetes and moderate cardiovascular risk compared to DPP-4 inhibitors and sulfonylureas.